Pharmacokinetics of PEGylated gold nanoparticles : in vitro-in vivo correlation
Dubaj, Tibor (Slovak University of Technology in Bratislava. Institute of Physical Chemistry and Chemical Physics)
Kozics, Katarina (Biomedical Research Center SAS. Cancer Research Institute (Bratislava, Eslovàquia))
Sramkova, Monika (Biomedical Research Center SAS. Cancer Research Institute (Bratislava, Eslovàquia))
Manova, Alena (Biomedical Research Center SAS. Cancer Research Institute (Bratislava, Eslovàquia))
Bastús, Neus G. (Institut Català de Nanociència i Nanotecnologia)
Moriones, Oscar Hernando (Institut Català de Nanociència i Nanotecnologia)
Kohl, Yvonne (Fraunhofer Institute for Biomedical Engineering)
Dusinska, Maria (Norwegian Institute for Air Research. Health Effects Laboratory)
Rundén-Pran, Elise (Norwegian Institute for Air Research. Health Effects Laboratory)
Puntes, Víctor (Institut Català de Nanociència i Nanotecnologia)
Nelson, Andrew (University of Leeds. School of Chemistry)
Gabelova, Alena (Biomedical Research Center SAS. Cancer Research Institute (Bratislava, Eslovàquia))
Šimon, Peter (Slovak University of Technology in Bratislava. Institute of Physical Chemistry and Chemical Physics)

Data:	2022
Resum:	Data suitable for assembling a physiologically-based pharmacokinetic (PBPK) model for nanoparticles (NPs) remain relatively scarce. Therefore, there is a trend in extrapolating the results of in vitro and in silico studies to in vivo nanoparticle hazard and risk assessment. To evaluate the reliability of such approach, a pharmacokinetic study was performed using the same polyethylene glycol-coated gold nanoparticles (PEG-AuNPs) in vitro and in vivo. As in vitro models, human cell lines TH1, A549, Hep G2, and 16HBE were employed. The in vivo PEG-AuNP biodistribution was assessed in rats. The internalization and exclusion of PEG-AuNPs in vitro were modeled as first-order rate processes with the partition coefficient describing the equilibrium distribution. The pharmacokinetic parameters were obtained by fitting the model to the in vitro data and subsequently used for PBPK simulation in vivo. Notable differences were observed in the internalized amount of Au in individual cell lines compared to the corresponding tissues in vivo, with the highest found for renal TH1 cells and kidneys. The main reason for these discrepancies is the absence of natural barriers in the in vitro conditions. Therefore, caution should be exercised when extrapolating in vitro data to predict the in vivo NP burden and response to exposure.
Ajuts:	European Commission 857381 European Commission 685817
Nota:	Altres ajuts: financial support from the Structural Funds of EU by implementation of the project "Strategic research in SMART monitoring, treatment, and prevention against coronavirus (SARS-CoV-2)", ITMS 2014+ code NFP313011ASS8 co-financed by the European Regional Development Fund.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Gold nanoparticles ; Human cell lines ; Pharmacokinetics ; PBPK model ; IVIVE
Publicat a:	Nanomaterials, Vol. 12, issue 3 (Feb. 2022) , art. 511, ISSN 2079-4991

DOI: 10.3390/nano12030511
PMID: 35159859

12 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències > Institut Català de Nanociència i Nanotecnologia (ICN2)
Articles > Articles de recerca
Articles > Articles publicats